C1071032 - MAGNETISMM-32 A PHASE 3, OPEN-LABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMB, POMALIDOMIDE, DEXAMETHASONE (EPd) OR POMALIDOMIDE, BORTEZOMIB, DEXAMETHASONE (PVd) OR CARFILZOMIB, DEXAMETHASONE (Kd) IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTI-CD38 DIRECTED THERAPY

Estado	Tipo de Participantes	Rangos de Edad
Reclutando	No aportado	Mayores de 64 , Adultos (18-64 años)
Género	**Fases**	**Participantes esperados**
Ambos	Fase III	79
Resultados	**Bajo nivel intervención**	**Enfermedad rara**
Sin resultados	No	No
Cobertura geográfica	**Ámbitos del ensayo**	**Terapia avanzada**
Sin determinar	tratamiento, seguridad, eficacia, farmacocinética, farmacogenética	NO

Información

Identificador
2023-507871-23-00 (CTIS)

Cod. Protocolo
C1071032

Área terapéutica
Enfermedades [C] - Hematología [C15]|

Enfermedad investigada
Relapsed/Refractory Multiple Myeloma

Título Científico

C1071032 - MAGNETISMM-32 A PHASE 3, OPEN-LABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB, POMALIDOMIDE, DEXAMETHASONE (EPd) OR POMALIDOMIDE, BORTEZOMIB, DEXAMETHASONE (PVd) OR CARFILZOMIB, DEXAMETHASONE (Kd) IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTI-CD38 DIRECTED THERAPY

Justificación

No aportado

Objetivo Principal

To compare the efficacy of elranatamab (Arm A) vs EPd or PVd or Kd (Arm B)

Variables de Evaluación Primaria

PFS (progression free survival) by BICR (blinded independent central review) per IMWG (International Myeloma Working Group)

Momentos temporales de evaluación primaria

No aportado

Objetivo Secundario

To compare the efficacy of elranatamab (Arm A) vs EPd or PVd or Kd (Arm B)
To determine the safety and tolerability of elranatamab monotherapy
To assess the safety and efficacy of elranatamab in US racial and ethnic minority participants
To evaluate the PK of elranatamab
To evaluate immunogenicity of elranatamab
To evaluate the impact of treatment on participant HRQoL (health related quality of life)

Variables de Evaluación Secundaria

OS (overall survival)
PFS by Investigator per IMWG PFS2 (PFS on next line therapy) by Investigator per IMWG ORR (objective response rate) by BICR per IMWG DOR (duration of response) by BICR per IMWG VGPRR (very good partial response rate) (VGPR) (very good partial response) by BICR per IMWG CRR (complete response rate) by BICR per IMWG DOCR (duration of complete response) by BICR per IMWG TTR (time to response) by BICR per IMWG
AEs (adverse events) Laboratory abnormalities
PFS by BICR per IMWG OS (overall survival) PFS and PFS2 by Investigator per IMWG ORR by BICR per IMWG DOR by BICR per IMWG VGPRR by BICR per IMWG CRR by BICR per IMWG DOCR by BICR per IMWG TTR by BICR per IMWG MRD negativity rate per IMWG Sustained MRD negativity rate for at least 12 months per IMWG AEs Laboratory abnormalities

Pre- and post-dose concentrations of elranatamab
ADA (antidrug antibody) and NAb (neutralizing antibody) against elranatamab
Change from baseline EORTC QLQ-C30 (European Organisation for Research and Treatment of Cancer Quality of Life Cancer Questionnaire 30) scores (global health, fatigue, pain, physical functioning, role functioning, and emotional functioning domains) Change from baseline MY20 (multiple myeloma module quality of life questionnaire) scores (disease symptoms, side-effects of treatment, body image, and future perspective domains)

Momentos temporales de evaluación secundaria

No aportado

Criterios de Inclusión

Participants aged 18 years or older (or the minimum age of consent in accordance with local regulations if 18) at screening. Prior diagnosis of MM (multiple myeloma) per IMWG criteria and previously received at least 1 but not more than 4 prior lines of therapy for MM including: At least 2 consecutive cycles of an anti-CD38 antibody-containing regimen in any prior line AND At least 2 consecutive cycles of a lenalidomide-containing regimen in any prior line Documented evidence of progressive disease or failure to achieve a response to last line of MM therapy based on investigator's determination of response by IMWG criteria. Measurable disease based on IMWG criteria as defined by at least 1 of the following (assessed by central laboratory): Serum M-protein (myeloma protein) 0.5 g/dL; Urinary M-protein excretion 200 mg/24 hours; Serum involved immunoglobulin FLC (free light chain) 10 mg/dL (100 mg/L) AND abnormal serum immunoglobulin kappa to lambda FLC ratio (<0.26 or >1.65). Corrected serum calcium 14 mg/dL (3.5 mmol/L), or free ionized calcium 6.5 mg/dL (1.6 mmol/L) Adequate bone marrow function (ANC, platelets, hemoglobin) ECOG (Eastern Cooperative Oncology Group) performance status <2.

Criterios de Exclusión

Plasma cell leukemia, Smoldering MM, Waldenströms macroglobulinemia, Amyloidosis, POEMS (Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal gammopathy and Skin abnormalities) Syndrome, known CNS (central nervous system) involvement or clinical signs of myelomatous meningeal involvement, stem cell transplant within 12 weeks prior to enrollment, active GVHD (graft versus host disease) (other than Grade 1 skin involvement) or GVHD requiring treatment. Unable to receive a control therapy (must be able and willing to adhere to any applicable requirements per Single Reference Safety Document [SRSD] for at least one choice of control therapy, including contraceptive requirements, and must not meet the exclusions listed below for the choice of control therapy): unable to receive PVd if any of the following are present: Received prior pomalidomide therapy Does not meet criteria for bortezomib retreatment, (ie, must not have progressive disease during treatment or within 60 days of the last dose of a bortezomib-containing regimen) Grade 1 peripheral neuropathy with pain or Grade 2 peripheral neuropathy as defined by NCI-CTCAE v5.0 Received a strong cytochrome P (CYP) 3A4 inducer within 5 half-lives prior to enrollment Active inflammatory gastrointestinal disease, chronic diarrhea, known diverticular disease or previous gastric resection or lap band surgery (gastroesophageal reflux disease under treatment with proton pump inhibitors is allowed, assuming no drug interaction potential). unable to receive Kd if any of the following are present: Received prior carfilzomib therapy Uncontrolled hypertension unable to receive EPd if any of the following are present: Received prior pomalidomide therapy Received prior elotuzumab therapy Active inflammatory gastrointestinal disease, chronic diarrhea, known diverticular disease or previous gastric resection or lap band surgery (gastroesophageal reflux disease under treatment with proton pump inhibitors is allowed, assuming no drug interaction potential). Live attenuated vaccines within 4 weeks of the first dose of study intervention; Cumulative dose of corticosteroids equivalent to 140 mg of prednisone (21 mg of dexamethasone) within the 14-day period before the first dose of study intervention, and administered for reasons other than anti-myeloma therapy Anti-myeloma drug therapy, within 14 days of the initiation of study intervention (includes dexamethasone). Bisphosphonate use

permitted. Impaired hepatic or renal function. Previous administration with an investigational product (drug or vaccine) within 30 days (or as determined by the local requirement) or 5 half lives preceding the first dose of study intervention used in this study (whichever is longer). Participation in studies of other investigational products (drug or vaccine) at any time during their participation in this study. Active HBV (Hepatitis B virus), HCV (Hepatitis C virus), SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), HIV [human immunodeficiency virus], or any active, uncontrolled bacterial, fungal, or viral infection. Active infections must be resolved at least 21 days prior to enrollment. Treatment with systemic anti-infective agents must have completed at least 28 days prior to enrollment. Prophylactic use of systemic anti-infective agents is permitted. Ongoing Grade 3 peripheral sensory or motor neuropathy; history of GBS (Guillain-Barré syndrome) or GBS variants; history of any Grade 3 peripheral motor polyneuropathy. Impaired cardiovascular function or clinically significant cardiovascular diseases within 6 months prior to enrollment, including LVEF (left ventricular ejection fraction) <40% as determined by a MUGA (multigated acquisition) scan or ECHO (echocardiogram) at screening. Any other active malignancy within 3 years prior to enrollment, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ or Stage 0/1 malignancy with minimal risk of recurrence per investigator Known or suspected hypersensitivity to the study interventions or any of their excipients. Unresolved acute effects (excluding alopecia) of any prior therapy (not resolved to baseline severity or CTCAE Grade 1). Previous treatment with a BCMA-directed or CD3 (cluster of differentiation 3) redirecting therapy. Individuals who have never achieved a response (partial response [PR] or better) with any treatment during the disease course.

Calendario

(Última actualización: 24/04/2026)

Autorización	Inicio de Ensayo	Inclusión Primer Paciente	Interrumpido	Reiniciado
09/05/2024	27/05/2024	26/08/2024	No aportado	No aportado

Fin de reclutamiento	Fin prematuro (España)	Fin prematuro (Global)	Fin del ensayo en España	Fin del ensayo global
No aportado	No aportado	No aportado	No aportado	No aportado

Promotor

Pfizer Inc. United States

66 Hudson Boulevard East

Contact Person

Clinical Medical Lead

+18007181021

ClinicalTrials.gov_Inquiries@pfizer.com

Monetary support: N/A

Tipo de promotor: Comercial

Ceim

CEIm Hospital Universitari Germans Trias i Pujol

Ctra. Canyet, s/n Edificio General - 1a planta / Módulos urgencias - 1a planta 08916 Badalona

ceic.germanstrias@gencat.cat

934978956

Centros

Activo (25/06/2024)

Hospital Clinic De Barcelona

Barcelona

BARCELONA

Hematology Unit

Activo (24/06/2024)

Hospital General Universitario Gregorio Maranon

Madrid

MADRID

Hematology Unit

No iniciado (--/--/----)

Hospital General Universitario Gregorio Maranon

Madrid

MADRID

Hematology Unit

Activo (06/03/2025)

Hospital General Universitario Morales Meseguer

Murcia

MURCIA

Hematology Unit

Activo (27/05/2024)

Hospital Universitari Mutua Terrassa

Terrassa

BARCELONA

Hematology Unit

Activo (19/06/2025)

Hospital Universitario De Cruces

Barakaldo

VIZCAYA/BIZKAIA

Hematology Unit

Activo (27/06/2024)

Hospital Universitario De Salamanca

Salamanca

SALAMANCA

Hematology Unit

Activo (28/02/2025)

Hospital Universitario Hm Sanchinarro

Madrid

MADRID

Hematology Unit

Cerrado (13/04/2026)

Hospital Universitario Infanta Leonor

Madrid

MADRID

Hematology Unit

Activo (06/03/2025)

Hospital Universitario Regional De Malaga

Malaga

MÁLAGA

Hematology Unit

Activo (28/06/2024)

Hospital Universitario Y Politecnico La Fe

Valencia

VALENCIA

Hematology Unit

No iniciado (--/--/----)

Institut Catala D´oncologia

Girona

GERONA

Hematology Unit

Activo (30/08/2024)

Institut Catala D´oncologia

Badalona

BARCELONA

Hematology Unit

Activo (19/06/2024)

Institut Catala D'oncologia

Girona

GERONA

Hematology Unit

Medicamentos

Dexamethason 0,5 mg JENAPHARM®
TABLET
ORAL USE

Código ATC: H02AB02 - DEXAMETASONA
Principios Activos: N/A

Experimental

Nodexon 20 mg tablets
TABLET
ORAL USE

Código ATC: H02AB02 - DEXAMETASONA
Principios Activos: N/A

Experimental

Bortezomib STADA 2,5 mg/ml Injektionslösung
SOLUTION FOR INJECTION
SUBCUTANEOUS OR INTRAVENOUS

Código ATC: L01XG01 - BORTEZOMIB
Principios Activos: N/A

Experimental

Imnovid 4 mg hard capsules
CAPSULE, HARD
ORAL USE

Código ATC: L04AX06 - POMALIDOMIDA
Principios Activos: N/A

Experimental

Dexamethason 4 mg JENAPHARM®
TABLET
ORAL USE

Código ATC: H02AB02 - DEXAMETASONA
Principios Activos: N/A

Experimental

Empliciti 400 mg powder for concentrate for solution for infusion.
SOLUTION FOR INFUSION
INTRAVENOUS USE

Código ATC: L01XC23 - ELOTUZUMAB
Principios Activos: N/A

Experimental

Kyprolis 60 mg powder for solution for infusion
SOLUTION FOR INFUSION
INTRAVENOUS USE

Código ATC: L01XG02 - CARFILZOMIB
Principios Activos: N/A

Huérfano
Experimental

Imnovid 1 mg hard capsules
CAPSULE, HARD
ORAL USE

Código ATC: L04AX06 - POMALIDOMIDA
Principios Activos: N/A

Experimental

ELRANATAMAB
SOLUTION FOR INJECTION
SUBCUTANEOUS USE

-

Principios Activos: N/A

Experimental

Imnovid 2 mg hard capsules
CAPSULE, HARD
ORAL USE

Código ATC: L04AX06 - POMALIDOMIDA
Principios Activos: N/A

Experimental

Nodexon 20 mg tabletes
TABLET
ORAL USE

Código ATC: H02AB02 - DEXAMETASONA
Principios Activos: N/A

Experimental

Privigen 100 mg/ml solution for infusion
SOLUTION FOR INFUSION
INTRAVENOUS USE

Código ATC: J06BA02 - INMUNOGLOBULINAS HUMANAS NORMALES PARA ADM. INTRAVASCULAR
Principios Activos: N/A

Experimental

Privigen 100 mg/ml solution for infusion
SOLUTION FOR INFUSION
INTRAVENOUS USE

Código ATC: J06BA02 - INMUNOGLOBULINAS HUMANAS NORMALES PARA ADM. INTRAVASCULAR
Principios Activos: N/A

Experimental

Imnovid 3 mg hard capsules
CAPSULE, HARD
ORAL USE

Código ATC: L04AX06 - POMALIDOMIDA
Principios Activos: N/A

Experimental

-
-
INTRAVENOUS USE

Código ATC: J06BA - INMUNOGLOBULINAS HUMANAS NORMALES
Principios Activos: N/A

Experimental

Sin resultados

C1071032 - MAGNETISMM-32 A PHASE 3, OPEN-LABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMB, POMALIDOMIDE, DEXAMETHASONE (EPd) OR POMALIDOMIDE, BORTEZOMIB, DEXAMETHASONE (PVd) OR CARFILZOMIB, DEXAMETHASONE (Kd) IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTI-CD38 DIRECTED THERAPY

State	Type of participants	Age Ranges
Recruiting	Not provided	Older than 64 , Adults (18-64 years)
Gender	**Phases**	**Expected Participants**
Both	Phase III	79
Results	**Low level of intervention**	**Rare disease**
No results	No	No
Geographic coverage	**Areas of the study**	**Advanced therapy**
Undetermined	treatment, safety, effectiveness, pharmacokinetics, pharmacogenetics	NO

Information

Identifier
2023-507871-23-00 (CTIS)

Protocol Code
C1071032

Therapeutic area
Diseases [C] - Hemic and Lymphatic Diseases [C15]|

Investigated Disease
Relapsed/Refractory Multiple Myeloma

Scientific Title

C1071032 - MAGNETISMM-32 A PHASE 3, OPEN-LABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB, POMALIDOMIDE, DEXAMETHASONE (EPd) OR POMALIDOMIDE, BORTEZOMIB, DEXAMETHASONE (PVd) OR CARFILZOMIB, DEXAMETHASONE (Kd) IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTI-CD38 DIRECTED THERAPY

Rationale

Not provided

Main Objective

To compare the efficacy of elranatamab (Arm A) vs EPd or PVd or Kd (Arm B)

Primary Endpoints

PFS (progression free survival) by BICR (blinded independent central review) per IMWG (International Myeloma Working Group)

Temporary moments of secondary assessment

Not provided

Secondary Objective

To compare the efficacy of elranatamab (Arm A) vs EPd or PVd or Kd (Arm B)
To determine the safety and tolerability of elranatamab monotherapy
To assess the safety and efficacy of elranatamab in US racial and ethnic minority participants
To evaluate the PK of elranatamab
To evaluate immunogenicity of elranatamab
To evaluate the impact of treatment on participant HRQoL (health related quality of life)

Secondary Endpoints

OS (overall survival)
PFS by Investigator per IMWG PFS2 (PFS on next line therapy) by Investigator per IMWG ORR (objective response rate) by BICR per IMWG DOR (duration of response) by BICR per IMWG VGPRR (very good partial response rate) (VGPR) (very good partial response) by BICR per IMWG CRR (complete response rate) by BICR per IMWG DOCR (duration of complete response) by BICR per IMWG TTR (time to response) by BICR per IMWG
AEs (adverse events) Laboratory abnormalities
PFS by BICR per IMWG OS (overall survival) PFS and PFS2 by Investigator per IMWG ORR by BICR per IMWG DOR by BICR per IMWG VGPRR by BICR per IMWG CRR by BICR per IMWG DOCR by BICR per IMWG TTR by BICR per IMWG MRD negativity rate per IMWG Sustained MRD negativity rate for at least 12 months per IMWG AEs Laboratory abnormalities

Pre- and post-dose concentrations of elranatamab
ADA (antidrug antibody) and NAb (neutralizing antibody) against elranatamab
Change from baseline EORTC QLQ-C30 (European Organisation for Research and Treatment of Cancer Quality of Life Cancer Questionnaire 30) scores (global health, fatigue, pain, physical functioning, role functioning, and emotional functioning domains) Change from baseline MY20 (multiple myeloma module quality of life questionnaire) scores (disease symptoms, side-effects of treatment, body image, and future perspective domains)

Temporary moments of secondary assessment

Not provided

Inclusion criteria

Participants aged 18 years or older (or the minimum age of consent in accordance with local regulations if 18) at screening. Prior diagnosis of MM (multiple myeloma) per IMWG criteria and previously received at least 1 but not more than 4 prior lines of therapy for MM including: At least 2 consecutive cycles of an anti-CD38 antibody-containing regimen in any prior line AND At least 2 consecutive cycles of a lenalidomide-containing regimen in any prior line Documented evidence of progressive disease or failure to achieve a response to last line of MM therapy based on investigator's determination of response by IMWG criteria. Measurable disease based on IMWG criteria as defined by at least 1 of the following (assessed by central laboratory): Serum M-protein (myeloma protein) 0.5 g/dL; Urinary M-protein excretion 200 mg/24 hours; Serum involved immunoglobulin FLC (free light chain) 10 mg/dL (100 mg/L) AND abnormal serum immunoglobulin kappa to lambda FLC ratio (<0.26 or >1.65). Corrected serum calcium 14 mg/dL (3.5 mmol/L), or free ionized calcium 6.5 mg/dL (1.6 mmol/L) Adequate bone marrow function (ANC, platelets, hemoglobin) ECOG (Eastern Cooperative Oncology Group) performance status <2.

Exclusion criteria

Plasma cell leukemia, Smoldering MM, Waldenströms macroglobulinemia, Amyloidosis, POEMS (Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal gammopathy and Skin abnormalities) Syndrome, known CNS (central nervous system) involvement or clinical signs of myelomatous meningeal involvement, stem cell transplant within 12 weeks prior to enrollment, active GVHD (graft versus host disease) (other than Grade 1 skin involvement) or GVHD requiring treatment. Unable to receive a control therapy (must be able and willing to adhere to any applicable requirements per Single Reference Safety Document [SRSD] for at least one choice of control therapy, including contraceptive requirements, and must not meet the exclusions listed below for the choice of control therapy): unable to receive PVd if any of the following are present: Received prior pomalidomide therapy Does not meet criteria for bortezomib retreatment, (ie, must not have progressive disease during treatment or within 60 days of the last dose of a bortezomib-containing regimen) Grade 1 peripheral neuropathy with pain or Grade 2 peripheral neuropathy as defined by NCI-CTCAE v5.0 Received a strong cytochrome P (CYP) 3A4 inducer within 5 half-lives prior to enrollment Active inflammatory gastrointestinal disease, chronic diarrhea, known diverticular disease or previous gastric resection or lap band surgery (gastroesophageal reflux disease under treatment with proton pump inhibitors is allowed, assuming no drug interaction potential). unable to receive Kd if any of the following are present: Received prior carfilzomib therapy Uncontrolled hypertension unable to receive EPd if any of the following are present: Received prior pomalidomide therapy Received prior elotuzumab therapy Active inflammatory gastrointestinal disease, chronic diarrhea, known diverticular disease or previous gastric resection or lap band surgery (gastroesophageal reflux disease under treatment with proton pump inhibitors is allowed, assuming no drug interaction potential). Live attenuated vaccines within 4 weeks of the first dose of study intervention; Cumulative dose of corticosteroids equivalent to 140 mg of prednisone (21 mg of dexamethasone) within the 14-day period before the first dose of study intervention, and administered for reasons other than anti-myeloma therapy Anti-myeloma drug therapy, within 14 days of the initiation of study intervention (includes dexamethasone). Bisphosphonate use

permitted. Impaired hepatic or renal function. Previous administration with an investigational product (drug or vaccine) within 30 days (or as determined by the local requirement) or 5 half lives preceding the first dose of study intervention used in this study (whichever is longer). Participation in studies of other investigational products (drug or vaccine) at any time during their participation in this study. Active HBV (Hepatitis B virus), HCV (Hepatitis C virus), SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), HIV [human immunodeficiency virus], or any active, uncontrolled bacterial, fungal, or viral infection. Active infections must be resolved at least 21 days prior to enrollment. Treatment with systemic anti-infective agents must have completed at least 28 days prior to enrollment. Prophylactic use of systemic anti-infective agents is permitted. Ongoing Grade 3 peripheral sensory or motor neuropathy; history of GBS (Guillain-Barré syndrome) or GBS variants; history of any Grade 3 peripheral motor polyneuropathy. Impaired cardiovascular function or clinically significant cardiovascular diseases within 6 months prior to enrollment, including LVEF (left ventricular ejection fraction) <40% as determined by a MUGA (multigated acquisition) scan or ECHO (echocardiogram) at screening. Any other active malignancy within 3 years prior to enrollment, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ or Stage 0/1 malignancy with minimal risk of recurrence per investigator Known or suspected hypersensitivity to the study interventions or any of their excipients. Unresolved acute effects (excluding alopecia) of any prior therapy (not resolved to baseline severity or CTCAE Grade 1). Previous treatment with a BCMA-directed or CD3 (cluster of differentiation 3) redirecting therapy. Individuals who have never achieved a response (partial response [PR] or better) with any treatment during the disease course.

Calendar

(Last Update: 24/04/2026)

Authorization	Start of Trial	First patient inclusion	Halted	Restarted
09/05/2024	27/05/2024	26/08/2024	Not aported	Not aported

End of recruitment	Premature end (Spain)	Premature End (Global)	Trial end (Spain)	Trial end (Global)
Not aported	Not aported	Not aported	Not aported	Not aported

Sponsor

Pfizer Inc. United States

66 Hudson Boulevard East

Contact Person

Clinical Medical Lead

+18007181021

ClinicalTrials.gov_Inquiries@pfizer.com

Monetary support: N/A

Sponsor type: Commercial

Ceim

CEIm Hospital Universitari Germans Trias i Pujol

Ctra. Canyet, s/n Edificio General - 1a planta / Módulos urgencias - 1a planta 08916 Badalona

ceic.germanstrias@gencat.cat

934978956

Sites

Active (25/06/2024)

Hospital Clinic De Barcelona

Barcelona

BARCELONA

Hematology Unit

Active (24/06/2024)

Hospital General Universitario Gregorio Maranon

Madrid

MADRID

Hematology Unit

not initialized (--/--/----)

Hospital General Universitario Gregorio Maranon

Madrid

MADRID

Hematology Unit

Active (06/03/2025)

Hospital General Universitario Morales Meseguer

Murcia

MURCIA

Hematology Unit

Active (27/05/2024)

Hospital Universitari Mutua Terrassa

Terrassa

BARCELONA

Hematology Unit

Active (19/06/2025)

Hospital Universitario De Cruces

Barakaldo

VIZCAYA/BIZKAIA

Hematology Unit

Active (27/06/2024)

Hospital Universitario De Salamanca

Salamanca

SALAMANCA

Hematology Unit

Active (28/02/2025)

Hospital Universitario Hm Sanchinarro

Madrid

MADRID

Hematology Unit

Closed (13/04/2026)

Hospital Universitario Infanta Leonor

Madrid

MADRID

Hematology Unit

Active (06/03/2025)

Hospital Universitario Regional De Malaga

Malaga

MÁLAGA

Hematology Unit

Active (28/06/2024)

Hospital Universitario Y Politecnico La Fe

Valencia

VALENCIA

Hematology Unit

not initialized (--/--/----)

Institut Catala D´oncologia

Girona

GERONA

Hematology Unit

Active (30/08/2024)

Institut Catala D´oncologia

Badalona

BARCELONA

Hematology Unit

Active (19/06/2024)

Institut Catala D'oncologia

Girona

GERONA

Hematology Unit

Medication

Dexamethason 0,5 mg JENAPHARM®
TABLET
ORAL USE

ATC code: H02AB02 - DEXAMETASONA
Active Principles: N/A

Experimental

Nodexon 20 mg tablets
TABLET
ORAL USE

ATC code: H02AB02 - DEXAMETASONA
Active Principles: N/A

Experimental

Bortezomib STADA 2,5 mg/ml Injektionslösung
SOLUTION FOR INJECTION
SUBCUTANEOUS OR INTRAVENOUS

ATC code: L01XG01 - BORTEZOMIB
Active Principles: N/A

Experimental

Imnovid 4 mg hard capsules
CAPSULE, HARD
ORAL USE

ATC code: L04AX06 - POMALIDOMIDA
Active Principles: N/A

Experimental

Dexamethason 4 mg JENAPHARM®
TABLET
ORAL USE

ATC code: H02AB02 - DEXAMETASONA
Active Principles: N/A

Experimental

Empliciti 400 mg powder for concentrate for solution for infusion.
SOLUTION FOR INFUSION
INTRAVENOUS USE

ATC code: L01XC23 - ELOTUZUMAB
Active Principles: N/A

Experimental

Kyprolis 60 mg powder for solution for infusion
SOLUTION FOR INFUSION
INTRAVENOUS USE

ATC code: L01XG02 - CARFILZOMIB
Active Principles: N/A

Orphan
Experimental

Imnovid 1 mg hard capsules
CAPSULE, HARD
ORAL USE

ATC code: L04AX06 - POMALIDOMIDA
Active Principles: N/A

Experimental

ELRANATAMAB
SOLUTION FOR INJECTION
SUBCUTANEOUS USE

-

Active Principles: N/A

Experimental

Imnovid 2 mg hard capsules
CAPSULE, HARD
ORAL USE

ATC code: L04AX06 - POMALIDOMIDA
Active Principles: N/A

Experimental

Nodexon 20 mg tabletes
TABLET
ORAL USE

ATC code: H02AB02 - DEXAMETASONA
Active Principles: N/A

Experimental

Privigen 100 mg/ml solution for infusion
SOLUTION FOR INFUSION
INTRAVENOUS USE

ATC code: J06BA02 - INMUNOGLOBULINAS HUMANAS NORMALES PARA ADM. INTRAVASCULAR
Active Principles: N/A

Experimental

Privigen 100 mg/ml solution for infusion
SOLUTION FOR INFUSION
INTRAVENOUS USE

ATC code: J06BA02 - INMUNOGLOBULINAS HUMANAS NORMALES PARA ADM. INTRAVASCULAR
Active Principles: N/A

Experimental

Imnovid 3 mg hard capsules
CAPSULE, HARD
ORAL USE

ATC code: L04AX06 - POMALIDOMIDA
Active Principles: N/A

Experimental

-
-
INTRAVENOUS USE

ATC code: J06BA - INMUNOGLOBULINAS HUMANAS NORMALES
Active Principles: N/A

Experimental

No results